

MyCare Psychiatry Paliperidone Assay Kit





This package insert must be read carefully prior to product use. Package insert instructions must be followed accordingly. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert.

CUSTOMER SERVICE



Telephone: +1 610 419-6731
 Fax: +1 484 547-0590
 Email: Techsupport@saladax.com
 116 Research Dr.
 Bethlehem, PA 18015 USA
 www.saladax.com



IVD	<i>in vitro</i> Diagnostic Device		Consult Instructions for Use
REF	Catalog Number		Use By
LOT	Batch Code (Lot)		Temperature Limitation
EC REP	Authorized Representative in the European Community		Manufacturer
Rx only	For Prescription Use Only	R1 R2	Reagent 1 Reagent 2

INTENDED USE

Rx only

The MyCare Psychiatry Paliperidone Assay Kit is intended for the *in vitro* quantitative measurement of paliperidone in human serum using automated clinical chemistry analyzers. Measurements obtained are used for monitoring patient adherence to paliperidone therapy to help ensure appropriate treatment.

SUMMARY AND EXPLANATION OF THE TEST

Paliperidone (3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one) is a benzisoxazole derivative, atypical antipsychotic agent used in the treatment of schizophrenia and schizoaffective disorder.^{1,2}

Nonadherence to medication is well known for patients with severe mental illness.³ While adherence to medication is critical to successful treatment outcomes, adherence is also least likely to be accurately assessed.^{4,5} Measurement of paliperidone provides clinicians with objective evidence of concentrations that may be related to patient adherence.⁶

The MyCare Paliperidone Assay Kit (US Patent 8,088,594) is a homogenous two reagent nanoparticle agglutination assay used for detection of paliperidone in human serum. It is based on competition between drug and drug-conjugates for binding to drug specific antibodies covalently bound to nanoparticles. The extent of particle aggregation can be followed spectrophotometrically on clinical chemistry analyzers.

REAGENTS

MyCare Paliperidone Assay Kit REF PAL-RGT	Quantity x Volume
Reagent 1 R1 Reaction buffer that contains drug-conjugate, protein and buffer	1 x 10.0mL
Reagent 2 R2 Nanoparticle reagent that contains monoclonal antibody bound to nanoparticles in a buffered solution	1 x 5.0 mL

WARNINGS AND PRECAUTIONS

- For In Vitro Diagnostic Use Only.
- For diagnostic purposes, the results should always be assessed with the patient's medical history, clinical examination and other findings.
- Exercise normal precautions required for handling all laboratory reagents.
- All components of the MyCare Paliperidone Assay Kit contain less than 0.1% sodium azide. Avoid contact with skin and mucous membranes. Flush affected areas with copious amounts of water. Seek immediate medical attention if reagents are ingested or come into contact with eyes. When disposing of such reagents, always flush with large amounts of water to prevent accumulation of azide.

REAGENT HANDLING

MyCare Paliperidone Assay Kit reagents are ready to use. Before use, mix the reagents by gently inverting three to five times, avoiding the formation of bubbles.

STORAGE AND STABILITY

Store reagents refrigerated at 2-8°C (35-46°F). Do not freeze.

When stored and handled as directed unopened reagents are stable until the expiration date. Improper storage of reagents can affect assay performance.

SPECIMEN COLLECTION AND HANDLING

Serum is required. Trough or C_{min} samples at steady state have been recommended for testing antipsychotics.⁶ After one week of treatment on the same dose, collect samples before the next dose.⁷ For long lasting injectables collect the sample before the next dose.⁶

Prepare serum within 3 days of blood collection. Blood and serum samples may be stored at room temperature or 2-8°C. Store serum for up to 7 days before measuring. Freeze ($\leq 20^{\circ}\text{C}$) for longer storage. Avoid repeated freezing and thawing of samples.

PROCEDURE

Materials Provided:

REF PAL-RGT – MyCare Paliperidone Assay Kit

Materials Required – Provided Separately:

REF MCP1-CAL – MyCare Psychiatry Calibrator Kit 1

REF MCP1-CON - MyCare Psychiatry Control Kit 1

Instruments

Reagents may need to be transferred to analyzer-specific reagent containers.

The performance of applications not validated by Saladax Biomedical, Inc. is not warranted and must be user defined.

Assay

To run the assay, see the instrument specific application sheet and appropriate analyzer operator's manual.

Calibration

Perform a full calibration using the six calibrators in the MyCare Psychiatry Calibrator Kit 1. Verify the calibration by testing the low, medium, and high controls in the MyCare Psychiatry Control Kit 1.

Calibration Frequency - Calibration is recommended:

- After a calibrator or reagent (kit) lot change,
- After performance of major instrument maintenance,
- As required following quality control procedures.

Quality Control (QC)

Each laboratory should establish its own QC procedures for the MyCare Paliperidone Assay Kit. All quality control requirements and testing should be performed in accordance with local, state and/or federal regulations or accreditation requirements. Good laboratory practice suggests that at least two QC concentrations be tested each day patient samples are measured, and each time calibration is performed. Ensure that the quality control results meet the acceptance criteria before reporting patient results.

RESULTS

The concentration result is automatically calculated from the non-linear calibration curve by the analyzer. Report results in ng/mL or nmol/L. The conversion factor from ng/mL is $2.35 \times \text{ng/mL} = \text{nmol/L}$.

LIMITATIONS OF THE PROCEDURE

The MyCare Paliperidone Assay Kit has been validated for serum. Do not use serum separator tubes.

As with any assay utilizing mouse antibodies, the possibility exists for interference by human anti-mouse antibodies (HAMA) in the sample. Samples containing such antibodies can potentially produce erroneous paliperidone results, which are inconsistent with the patient's clinical profile.

Haloperidol when tested at 25 ng/mL had a cross-reactivity in the assay of $\leq 32\%$. Fentanyl when tested at 100 ng/mL had a cross-reactivity in

the assay of $\leq 9\%$. Trazodone tested at 6,000 ng/mL had a cross-reactivity of 1%. Therefore, high therapeutic concentrations of trazodone may cause a bias in results. Elevated levels of paliperidone may be seen in patients administered haloperidol, fentanyl or trazodone.

EXPECTED VALUES

The therapeutic range for paliperidone in serum is not fully established. A therapeutic range from 20 to 60 ng/mL has been proposed.⁶ Measured concentrations for adherent patients at steady-state are expected to be in the measuring range of the assay. Therapeutic drug monitoring of paliperidone has been recommended because of high interpatient variability, unpredictable response, and the importance of adherence for successful therapy.⁶ The complexity of the clinical state, individual differences in sensitivity, and co-administered medications may contribute to different requirements for optimal paliperidone blood levels. Users should investigate the transferability of the expected values to their own patient population and if necessary determine their own reference range. For diagnostic purposes the test findings should always be assessed in conjunction with the patient's medical history, clinical examinations, and other findings. Clinicians should carefully monitor patients during therapy initiation and dose adjustments. It may be necessary to obtain multiple samples to determine expected variation of optimal (steady-state) concentrations for individual patients.

SPECIFIC PERFORMANCE DATA

Typical performance data for the MyCare Paliperidone Assay Kit obtained on a Beckman Coulter® AU480 are shown below. Results obtained in individual laboratories may differ from these data.

Precision

Within-laboratory precision and repeatability were verified throughout the measuring range according to CLSI Guideline EP05-A3.⁸ Three MyCare Psychiatry Control Kit 1 controls, three paliperidone spiked pools (Serum 1, 2, 3) and two pools of clinical samples (Clinical 1, 2) were tested.

Sample	N	Mean (ng/mL)	Repeatability	Within-Laboratory
			CV	CV
Control 1	80	36	2.8%	3.7%
Control 2	80	65	2.1%	2.8%
Control 3	80	99	2.5%	3.3%
Serum 1	80	22	3.9%	9.0%
Serum 2	80	63	5.0%	5.1%
Serum 3	80	85	5.6%	5.9%
Clinical 1	80	21	3.0%	4.3%
Clinical 2	80	63	2.5%	3.5%

Limit of Quantitation (LoQ) and Limit of Detection (LoD)

The lower limits of quantitation and detection were established using CLSI guideline EP17-A2.⁹

LoQ

The LoQ was determined with an accuracy goal at the LoQ of $\leq 35\%$ total error (Westgard model). The LoQ of the MyCare Paliperidone Assay Kit is 16 ng/mL.

LoD

The LoD is the lowest amount of analyte that can be reliably detected (≥ 95 of results greater than the limit of blank.). The LoD of the MyCare Paliperidone Assay Kit is 7 ng/mL.

Result Reporting

Each laboratory should determine reporting criteria for paliperidone concentrations. The following suggestion from CLSI EP17-A2 may be appropriate:⁹

Result \leq LoB - report "not detected; concentration < LoD"

LoB < Result < LoQ - report "analyte detected; concentration < LoQ"

Result \geq LoQ - report the result as measured

Measurement Range

The measurement range of the MyCare Paliperidone Assay Kit is 16 – 120 ng/mL.

Specificity

Metabolism

Paliperidone itself is not extensively metabolized.¹⁰ No metabolites have been detected in plasma and paliperidone accounts for 97% of the area under the curve at 24 hours.¹¹

Specificity for the following cross-reactants was tested in the absence and presence of paliperidone at 20 and 60 ng/mL.

Cross-reactivity

The following compounds did not interfere with the MyCare Paliperidone Assay Kit: cross reactivity was $\leq 3\%$ or the assay bias was $\leq 13\%$.

Compound	Tested at (ng/mL)	Compound	Tested at (ng/mL)
Acetaminophen	200,000	Acetazolamide	60,000
Acetylsalicylic acid	500,000	Albuterol	1,000
Alendronate sodium	1,000	Alpha - tocopherol	40,000
Alprazolam	2,000	Amantadine	10,000
Amikacin sulfate	100,000	Amiloride HCl dihydrate	500
Amisulpride	400	Amitriptyline	1,000
Amlodipine besylate	100	Amoxicillin	80,000
S (+)-amphetamine	1,000	Aripiprazole	500
L-ascorbic acid	60,000	Atomoxetine	5,000
Atorvastatin calcium	600	Baclofen	3,000
Benzotropine	400	Betamethasone	100
Biotin	300	Biperiden	100
Budesonide	2.2	Bupropion	3,000
Buspirone	20	Caffeine	60,000
Calcium carbonate	300,000	Carbamazepine	30,000
Cefalexin	200,000	Celecoxib	1,000
Cetirizine dihydrochloride	3,500	8-chlorotheophylline	3,000
Chlorpromazine HCl	2,500	Cimetidine	20,000
Ciprofloxacin	10,000	Citalopram HBr	750

Compound	Tested at (ng/mL)	Compound	Tested at (ng/mL)
Clindamycin	50,000	Clonazepam	150
Clotrimazole	50	Clozapine	1,000
Codeine	2,000	Cortisol	300
(-)-cotinine	2,000	Desloratadine	600
Desvenlafaxine	400	Dextromethorphan	1,000
Diazepam	6,000	Diphenhydramine HCl	6,000
Docosahexaenoic acid ethyl ester	150,000	Doxycycline HCl	35,000
Duloxetine	200	Erythromycin	60,000
Escitalopram	100	Estradiol	1.2
Eszopiclone	200	Ethanol	4,000,000
Famotidine	600	Fenofibrate	50,000
Fluoxetine HCl	4,000	Fluticasone propionate	1
Folic acid	15	Furosemide	60,000
Gentamycin sulfate	30,000	Glyburide	2,000
Haloperidol decanoate	1,500	Heparin sodium salt	3 U/mL
Hydrochlorothiazide	6,000	Ibuprofen	500,000
lloperidone	10	Indinavir sulfate	400
Lamivudine	2,000	Lamotrigine	15,000
Lansoprazole	1,000	Lisinopril dihydrate	350
Lithium carbonate	250,000	Lorazepam	1,000
Lovastatin	500	Meclizine	500
Metformin	40,000	Methotrimeprazine	200
Methylphenidate HCl	350	Metoclopramide HCl	500
Metoprolol tartrate	5,000	Metronidazole	120,000
Mirtazapine	300	Mometasone furoate	1
Morphine	500	Naproxen sodium	500,000
Nateglinide	20,000	N-desalkyl risperidone	20
Nefazodone HCl	3,500	Nicotinic acid	20,000
Nordiazepam	5,000	Nortriptyline	1,000
Olanzapine	300	Omeprazole	6,000
Oxazepam	5,000	Oxcarbazepine	35,000
Oxycodone	500	Pantothenic acid	150
Paroxetine	1,000	Penicillin V	6,000
Perphenazine	100	Phentermine	500
Pimozide	20	Pipamperone dihydrochloride	400
Potassium EDTA	1,000	Pravastatin sodium	150
Prednisolone	3,000	Pregabalin	5,000
Promethazine	1,200	R,R (-)-pseudoephedrine	10,000

Compound	Tested at (ng/mL)	Compound	Tested at (ng/mL)
S,S (-)-pseudoephedrine	10,000	Pyridoxine HCl	100
Quetiapine	500	Quinidine	12,000
Ranitidine	6,000	Retinol	4,000
Riboflavin	200	Rosuvastatin calcium	50
Salicylic acid	500,000	Sertraline hydrochloride	600
Simvastatin	30	Sodium fluoride	150
Spironolactone	600	Sulfamethoxazole	400,000
Temazepam	5,000	Theophylline	40,000
Thiamine HCl	50	Topiramate	10,000
Triamcinolone acetonide	10	Triamterene	9,000
Triazolam	40	Valproic acid	500,000
Vancomycin HCl	100,000	Venlafaxine HCl	400
Vitamin B12	1	Vitamin D2	40
Vitamin K1	1	Warfarin	10,000
Ziprasidone	200	Zolpidem hemitartrate	5,000
Zonisamide	40,000	Zopiclone	100

Interfering Substances: No significant assay bias was observed from samples with the following endogenous interferents at the given levels:

Interferent	Level	
Rheumatoid Factor	508 IU/mL	
Total Protein Matrix Effect	11.0 g/dL	110 g/L
Icteric Interference	18.32 mg/dL	313 µmol/L
Lipemic Interference	1,828 mg/dL	30 mmol/L
Hemolysate	210 mg/dL	

Recovery

To assess recovery paliperidone was spiked into four individual paliperidone-free serum samples. The percent recovery was determined by dividing the measured concentration of each sample by the expected concentration of added paliperidone. The percent recovery ranged from 90 to 113%.

Linearity

The linearity of the MyCare Paliperidone Assay Kit was verified according to CLSI guideline EP6-A.¹² Eleven linearity samples covering the measuring range were prepared in human serum spiked with paliperidone. Deviation from linearity (n=5) was < 6%. The assay was linear across the measuring range from 16 – 120 ng/mL.

Method Comparison

Results of the MyCare Paliperidone Assay Kit were compared to a validated LC-MS/MS according to CLSI guideline EP09-A3.¹³ Deming regression analysis was performed with 119 patient samples. Results are shown for one lot.

Deming Regression statistics MyCare Paliperidone Assay Kit vs. LC-MS/MS	
Slope	1.00
Intercept	2.86
Correlation Coefficient (R)	0.94
N	119
Concentration Range (LC-MS/MS)	16 – 120 ng/mL

References

- Janssen Pharmaceuticals, Inc. Invega® (paliperidone) Prescribing information. 2017.
- Janssen Pharmaceuticals, Inc. Invega Sustenna® (paliperidone palmitate) extended-release injectable suspension Prescribing Information. 2017.
- Velligan DI, Weiden PJ, Sajatovic M, et al. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the Expert Consensus Guidelines. *J Psychiatr Pract.* 2010;16(1):34-45.
- Higashi K, Medic G, Littlewood KJ, Diez T, Granstrom O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. *Ther Adv Psychopharmacol.* 2013;3(4):200-218.
- Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. *Patient Relat Outcome Meas.* 2014;5:43-62.
- Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. *Pharmacopsychiatry.* 2018;51:9-62.
- Grundmann M, Kacirova I, Urinovska R. Therapeutic drug monitoring of atypical antipsychotic drugs. *Acta Pharm.* 2014;64(4):387-401.
- CLSI. Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Second Edition. CLSI document EP05-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2014.
- CLSI. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline – Second Edition. CLSI document EP17-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
- Spina E, Cavallaro R. The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. *Expert Opin Drug Saf.* 2007;6(6):651-662.
- Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. *Drug Metab Dispos.* 2008;36(4):769-779.
- NCCLS. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline. NCCLS document EP6-A. Wayne, PA: NCCLS; 2003.
- CLSI. Measurement Procedure and Bias Estimation Using Patient Samples; Approved Guideline-Third Edition. CLSI document EP09-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.

© 2018, Saladax Biomedical, Inc.

MyCare is a trademark of Saladax Biomedical, In. All other product names and trademarks are property of their respective owners.